Mobia Medical, Inc. operates as a commercial-stage medical device company dedicated to redefining stroke recovery for survivors with life-altering motor impairments. The company's core offering is the Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System, which is the first and only clinically validated, FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors. The Vivistim Therapy leverages neuroplasticity by combining targeted vagus nerve stimulation with functional movement and physical therapy, offering both in-clinic and at-home therapy components.
Mobia Medical generates its revenue entirely from the sale of the Vivistim System to healthcare providers, primarily targeting primary and comprehensive stroke centers across the United States. The company has established a network of therapy sites to support its commercial launch, which began in 2023. As of early 2026, the company had performed over 1,000 implants and reported significant revenue growth, though it continues to operate at a net loss as it invests heavily in expanding its direct sales force, commercial organization, and ongoing research and development. The company's competitive position is strengthened by its proprietary, purpose-built technology and a robust intellectual property portfolio, positioning it as a pioneer in the neurostimulation market for stroke rehabilitation.
